Bayer's adjusted EBITDA for the third quarter rose nearly 21%, beating expectations

AASTOCKS
2025.11.12 07:35

German pharmaceutical and chemical giant Bayer announced its third-quarter results, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rising 20.8% to €1.51 billion, exceeding market expectations of €1.29 billion. Sales fell 3.1% year-on-year to €9.66 billion, which was below expectations; the adjusted EBITDA margin increased by 3 percentage points year-on-year to 15.6%.

CEO Bill Anderson is working to rebuild investor trust in Bayer. The company is facing numerous legal disputes in the U.S. due to its herbicide "Roundup" and other chemical products inherited from its acquisition of Monsanto in 2018. Anderson has pledged to significantly control legal risks by the end of next year while implementing an efficiency improvement plan that has already cut thousands of jobs.

Bayer's stock price has risen over 40% this year to date, with analysts betting on a business turnaround, but the stock price remains well below levels prior to the Monsanto deal

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.